KM Research Hub
← 返回结果库查看论文详情PubMed ↗
READ-ONLY DIGITIZATION RESULT

Fuzuloparib with or without apatinib as maintenance therapy in newly diagnosed, advanced ovarian cancer (FZOCUS-1): A multicenter, randomized, double-blind, placebo-controlled phase 3 trial.

CA Cancer J Clin · 2026 · PMID 41287969

Panel B质量警告待 EXE 对齐验证

PFS

FIGURE 3 Progression‐free survival assessed by a blinded independent review committee in (A) the HRD subgroup and (B) the HRP subgroup. Tick marks indicate the time points at which data were censored. CI indicates confidence interval; HR, hazard ratio; HRD, homologous recombination deficiency; HRP, homologous recombination proficient; NR, not reached; PFS, progression‐free survival.

算法:legacy-0.5.0引擎:enhanced-linux
质量评分0.15
质量通过否
预期曲线3
实际曲线1
X 范围0 – 50
Y 范围0 – 100

曲线数据

网页最多预览 200 行,完整数据请下载 CSV 或 JSON。

匹配 14 行
Curve序号X (norm)Y (norm)X (real)Y (real)X (pixel)Y (pixel)
310.00000.14010.000014.009786207
320.08400.07734.20107.7295137220
330.08570.07254.28347.2464138221
340.08730.07254.36577.2464139221
350.08900.07254.44817.2464140221
360.09060.07254.53057.2464141221
370.09230.07254.61297.2464142221
380.09390.07254.69527.2464143221
390.09560.07254.77767.2464144221
3100.09720.07254.86007.2464145221
3110.09880.07254.94237.2464146221
3120.10050.07255.02477.2464147221
3130.10210.07255.10717.2464148221
3140.10380.07255.18957.2464149221
历史版本(1)

重跑只新增版本,不覆盖旧结果;正式可用状态仅授予通过 EXE 基准或人工复核的版本。

版本状态验证曲线时间
legacy-0.5.0quality_warning待验证12026-07-23T17:11:30+00:00